Goldman Sachs
INDV icon

Goldman Sachs’s Indivior Pharmaceuticals INDV Stock Holding History

Goldman Sachs’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6M Sell
696,268
-1,712,897
-71% -$62.1M ﹤0.01% 2313
2026
Q1 		$73.4M Sell
2,409,165
-768,702
-24% -$25.4M 0.01% 1266
2025
Q4 		$114M Sell
3,177,867
-3,398,981
-52% -$104M 0.01% 913
2025
Q3 		$159M Sell
6,576,848
-2,987,243
-31% -$62.5M 0.02% 702
2025
Q2 		$141M Buy
9,564,091
+1,195,095
+14% +$13.9M 0.02% 717
2025
Q1 		$79.8M Buy
8,368,996
+1,299,425
+18% +$13.7M 0.01% 906
2024
Q4 		$87.9M Buy
7,069,571
+2,121,926
+43% +$21.8M 0.01% 885
2024
Q3 		$48.2M Buy
4,947,645
+3,551,179
+254% +$41.6M 0.01% 1275
2024
Q2 		$22.5M Sell
1,396,466
-3,263,921
-70% -$58.9M ﹤0.01% 1795
2024
Q1 		$99.8M Buy
4,660,387
+201,850
+5% +$3.79M 0.02% 784
2023
Q4 		$68.1M Sell
4,458,537
-1,224,501
-22% -$21.7M 0.01% 978
2023
Q3 		$131M Buy
5,683,038
+2,167,145
+62% +$49.4M 0.03% 593
2023
Q2 		$83.7M Buy
+3,515,893
New +$80.6M 0.02% 801

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's INDV Position: Q2 2026 in Review

Goldman Sachs reduced its Indivior Pharmaceuticals (INDV) stake by 71% in Q2 2026, selling an estimated $62.1M and leaving 696,268 shares worth $28.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

Goldman Sachs first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $159M in Q3 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Goldman Sachs held 696,268 shares of Indivior Pharmaceuticals worth $28.6M as of Q2 2026.
  • Goldman Sachs sold 1,712,897 Indivior Pharmaceuticals shares in Q2 2026, an estimated $62.1M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2313 holding.
  • Goldman Sachs first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Goldman Sachs's Indivior Pharmaceuticals position peaked at $159M in Q3 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.